China Universal Asset Management Co. Ltd. Raises Stock Position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)

China Universal Asset Management Co. Ltd. grew its position in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) by 359.3% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,951 shares of the company’s stock after buying an additional 3,873 shares during the quarter. China Universal Asset Management Co. Ltd.’s holdings in 4D Molecular Therapeutics were worth $100,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently modified their holdings of the company. RA Capital Management L.P. raised its position in 4D Molecular Therapeutics by 35.6% in the third quarter. RA Capital Management L.P. now owns 4,163,211 shares of the company’s stock worth $52,998,000 after acquiring an additional 1,093,680 shares during the period. BlackRock Inc. increased its stake in shares of 4D Molecular Therapeutics by 14.3% in the 2nd quarter. BlackRock Inc. now owns 2,914,430 shares of the company’s stock worth $52,664,000 after purchasing an additional 363,695 shares in the last quarter. State Street Corp raised its holdings in 4D Molecular Therapeutics by 0.4% in the 2nd quarter. State Street Corp now owns 2,050,430 shares of the company’s stock worth $37,051,000 after purchasing an additional 8,241 shares during the period. Vanguard Group Inc. lifted its position in 4D Molecular Therapeutics by 0.6% during the first quarter. Vanguard Group Inc. now owns 1,290,941 shares of the company’s stock valued at $19,519,000 after purchasing an additional 7,858 shares in the last quarter. Finally, ArrowMark Colorado Holdings LLC grew its holdings in 4D Molecular Therapeutics by 5.1% during the first quarter. ArrowMark Colorado Holdings LLC now owns 1,032,719 shares of the company’s stock valued at $17,752,000 after purchasing an additional 50,520 shares during the period. 99.27% of the stock is currently owned by hedge funds and other institutional investors.

4D Molecular Therapeutics Stock Up 3.5 %

Shares of 4D Molecular Therapeutics stock opened at $28.60 on Friday. 4D Molecular Therapeutics, Inc. has a twelve month low of $9.44 and a twelve month high of $36.25. The business has a 50-day moving average price of $28.37 and a 200-day moving average price of $19.34. The firm has a market cap of $1.42 billion, a price-to-earnings ratio of -10.75 and a beta of 2.87.

4D Molecular Therapeutics (NASDAQ:FDMT) last released its quarterly earnings results on Thursday, February 29th. The company reported ($0.77) earnings per share for the quarter, missing the consensus estimate of ($0.68) by ($0.09). The firm had revenue of ($0.02) million for the quarter, compared to analysts’ expectations of $4.67 million. 4D Molecular Therapeutics had a negative net margin of 436.30% and a negative return on equity of 34.14%. On average, equities analysts expect that 4D Molecular Therapeutics, Inc. will post -3.03 EPS for the current fiscal year.

Wall Street Analyst Weigh In

FDMT has been the topic of a number of analyst reports. The Goldman Sachs Group reaffirmed a “buy” rating and set a $81.00 price objective on shares of 4D Molecular Therapeutics in a research report on Wednesday, February 7th. BMO Capital Markets lowered their price target on shares of 4D Molecular Therapeutics from $70.00 to $63.00 and set an “outperform” rating on the stock in a report on Monday, April 1st. HC Wainwright reissued a “buy” rating and issued a $36.00 price objective on shares of 4D Molecular Therapeutics in a research note on Friday, March 1st. Royal Bank of Canada lifted their target price on shares of 4D Molecular Therapeutics from $25.00 to $35.00 and gave the company an “outperform” rating in a research note on Monday, February 5th. Finally, Jefferies Financial Group increased their price target on 4D Molecular Therapeutics from $30.00 to $58.00 and gave the stock a “buy” rating in a research note on Monday, April 1st. One analyst has rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat, 4D Molecular Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $40.60.

Insider Activity at 4D Molecular Therapeutics

In related news, insider Scott Bizily sold 5,833 shares of the company’s stock in a transaction on Wednesday, March 27th. The shares were sold at an average price of $35.04, for a total transaction of $204,388.32. Following the sale, the insider now owns 1,737 shares of the company’s stock, valued at $60,864.48. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other news, CEO David Kirn sold 92,001 shares of the firm’s stock in a transaction that occurred on Thursday, February 8th. The stock was sold at an average price of $27.13, for a total value of $2,495,987.13. Following the completion of the sale, the chief executive officer now directly owns 1,059,153 shares of the company’s stock, valued at approximately $28,734,820.89. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Scott Bizily sold 5,833 shares of the business’s stock in a transaction that occurred on Wednesday, March 27th. The shares were sold at an average price of $35.04, for a total value of $204,388.32. Following the transaction, the insider now directly owns 1,737 shares in the company, valued at approximately $60,864.48. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 147,888 shares of company stock valued at $4,134,254. 10.70% of the stock is owned by corporate insiders.

4D Molecular Therapeutics Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.